Sialic Acid As A Potential Biomarker for Cardiovascular Disease, Diabetes and Cancer
Jack Cheeseman, Gunter Kuhnle, Graham P. Stafford, Richard A. Gardner, Daniel I. R. Spencer, Helen M. I. Osborn
Abstract
Cardiovascular disease (CVD), diabetes and cancer pose increasing global healthcare burdens. New biomarkers could enable earlier diagnosis of these diseases, leading to more effective treatment and lower associated healthcare burden. Elevated sialic acid concentration in plasma and serum has been positively correlated with the presence of CVDs, diabetes and the development of malignant tumors. This article reviews the use of total sialic acid (TSA), bound sialic acid (BSA) and free sialic acid (FSA) as potential biomarkers for these diseases and makes a comparison with existing markers. Elevated sialic acid has been shown to be indicative of the pathogenesis of CVD, diabetes and malignant tumors. While not a specific marker for one disease there is promise in utilizing sialic acid as a marker for monitoring disease progression and effectiveness of treatment programs.